Clinical Trials Browser

Terminated × INDUSTRY × camrelizumab × Clear all

NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Phase 3 Terminated

Non-squamous Non-small-cell Lung Cancer

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Phase 1 Terminated

Advanced Tumors

NCT03711279 2024-02-29

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Phase 2 Terminated

99 enrolled 10 charts

Sarcoma

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Phase 3 Terminated

Advanced NSCLC

NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumor

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor

NCT03666728 2021-03-17

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Phase 2 Terminated

Lung Neoplasms

NCT03645876 2019-05-10

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms